Skip to search formSkip to main contentSkip to account menu

CDP870

Known as: CDP870s, 870s, CDP, 870, CDP 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
BACKGROUND Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) for… 
Review
2010
Review
2010
  • Y. WuB. Zhou
  • British Journal of Cancer
  • 2010
  • Corpus ID: 14944496
Tumour necrosis factor-alpha (TNF-α) is an important inflammatory factor that acts as a master switch in establishing an… 
Review
2010
Review
2010
Tumor necrosis factor (TNF)-α is implicated in the same time in apoptosis and in cell proliferation. TNF-α not only acts as pro… 
Review
2009
Review
2009
  • A. Rivkin
  • Clinical Therapeutics
  • 2009
  • Corpus ID: 26469956
Highly Cited
2007
Highly Cited
2007
Background: Inhibitors of tumor necrosis factor &agr; (TNF&agr;) have demonstrated significant efficacy in chronic inflammatory… 
Review
2006
Review
2006
In the past decade, advances in the understanding of the pathogenesis of inflammatory bowel disease have permitted the… 
Highly Cited
2005
Highly Cited
2005
BACKGROUND & AIMS To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti… 
Highly Cited
2004
Highly Cited
2004
Absorption Prediction.- Predicting Molecular Physical Properties.- In Silico Transporter Modeling and Its Application in Drug… 
Highly Cited
2004
Highly Cited
2004
Background : CDP870 is a PEGylated Fab′ fragment of a humanized monoclonal antibody that neutralizes tumour necrosis factor‐α. 
Highly Cited
2002
Highly Cited
2002
OBJECTIVE Biological products that neutralize tumour necrosis factor alpha (TNF-alpha) are beneficial in rheumatoid arthritis (RA…